Etelcalcetide — Discount Pricing

Other medications in Diabetes & Metabolism

• Exenatide
• Finerenone
• Glimepiride
• Glipizide
• Glyburide
• Insulin Aspart
• Insulin Degludec
• Insulin Detemir

About Etelcalcetide

Etelcalcetide, known commercially as Parsabiv, offers a vital treatment for adults on hemodialysis battling secondary hyperparathyroidism. This injectable medication helps manage critical mineral imbalances that can impact bone health and overall well-being. Understanding its role and potential costs is crucial, and TheDrugClub is here to help members navigate these expenses with significant savings on their prescriptions.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Etelcalcetide is approved for (FDA label)

PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. PARSABIV is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ( 1 ) Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations. Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations .

Source: Read the full FDA label on DailyMed. Label effective date: March 8, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Etelcalcetide (FDA label)

PARSABIV is a single-dose, clear, and colorless solution available as follows: Injection: 2.5 mg/0.5 mL solution in a single-dose vial Injection: 5 mg/mL solution in a single-dose vial Injection: 10 mg/2 mL solution (5 mg/mL) in a single-dose vial Injection: 2.5 mg/0.5 mL solution in a single-dose vial ( 3 ) Injection: 5 mg/mL solution in a single-dose vial ( 3 ) Injection: 10 mg/2 mL solution in a single-dose vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c. SPL document ID: 52286976-a97a-4b77-b678-f40ab5aa7133. Label effective date: March 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Etelcalcetide (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: Hypocalcemia [see Warnings and Precautions (5.1) ] Worsening Heart Failure [see Warnings and Precautions (5.2) ] Upper Gastrointestinal Bleeding [see Warnings and Precautions (5.3) ] Adynamic Bone [see Warnings and Precautions (5.4) ] The most common adverse reactions (≥ 5%) were blood calcium decreased, muscle spasms, diarrhea, nausea, vomiting, headache, hypocalcemia, and paresthesia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c. SPL document ID: 52286976-a97a-4b77-b678-f40ab5aa7133. Label effective date: March 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Etelcalcetide (FDA label)

PARSABIV is contraindicated in patients with known hypersensitivity to etelcalcetide or any of its excipients. ( 4 ) Hypersensitivity PARSABIV is contraindicated in patients with known hypersensitivity to etelcalcetide or any of its excipients. Hypersensitivity reactions, including face edema and anaphylactic reaction, have occurred with PARSABIV [see Adverse Reactions (6) ] .

Source: FDA prescribing information (DailyMed). Set ID: cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c. SPL document ID: 52286976-a97a-4b77-b678-f40ab5aa7133. Label effective date: March 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Etelcalcetide (FDA label)

Hypocalcemia: Sometimes severe. Severe hypocalcemia can cause paresthesias, myalgias, muscle spasms, seizures, QT prolongation, and ventricular arrhythmias. Patients predisposed to QT interval prolongation, ventricular arrhythmias, and seizures may be at increased risk and require close monitoring. Educate patients on the symptoms of hypocalcemia and advise them to contact a healthcare provider if they occur. ( 5.1 ) Worsening Heart Failure: Reductions in corrected serum calcium may be associated with congestive heart failure, however, a causal relationship to PARSABIV could not be completely excluded. Closely monitor patients for worsening signs and symptoms of heart failure. ( 5.2 ) Upper Gastrointestinal (GI) Bleeding: Patients with risk factors for upper GI bleeding may be at increased risk. Monitor patients and promptly evaluate and treat any suspected GI bleeding. ( 5.3 ) Adynamic Bone: May develop if PTH levels are chronically suppressed.

Source: FDA prescribing information (DailyMed). Set ID: cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c. SPL document ID: 52286976-a97a-4b77-b678-f40ab5aa7133. Label effective date: March 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.